PMID- 27491230
OWN - NLM
STAT- MEDLINE
DCOM- 20160930
LR  - 20181202
IS  - 1003-5370 (Print)
IS  - 1003-5370 (Linking)
VI  - 36
IP  - 6
DP  - 2016 Jun
TI  - [Danlou Tablet Fought against Inflammatory Reaction in Atherosclerosis Rats with 
      Intermingled Phlegm and Blood Stasis Syndrome and Its Mechanism Study].
PG  - 703-8
AB  - OBJECTIVE: To observe the effects of Danlou Tablet (DT) on inflammatory reaction, 
      and expressions of lipoprotein-associated phospholipase A2 (LP-PLA2), secretory 
      phospholipase A2 (sPLA2), and to analyze potential mechanisms. METHODS: Forty 
      male Wistar rats were randomly and equally divided into five groups, i.e., the 
      normal control group, the model group, the Western medicine (WM) group, the low 
      dose DT group, the high dose DT group, 8 in each group. Rats in the normal 
      control group were fed with basic forage for 12 successive weeks, while AS rat 
      model was established in rats of the other four groups by feeding high fat and 
      sugar forage plus intraperitoneal injection of vitamin D(3). Normal saline, 
      atorvastatin calcium suspension (at the daily dose of 1.8 mg/kg), low dose DT 
      suspension (at the daily dose of 450 mg/kg), and high dose DT suspension (at the 
      daily dose of 900 mg/kg) were administered to rats in the model group, the WM 
      group, the low dose DT group, the high dose DT group respectively by gastragavage 
      for 8 successive weeks. The general condition of all rats was observed. Rats were 
      sacrificed after gastric administration and their serum collected. Serum levels 
      of lipids (TC, TG, HDL-C, LDL-C) and inflammatory factors [IL-6, TNF-alpha, monocyte 
      chemoattractant protein 1 (MCP-1), oxidized low-density lipoprotein (ox-LDL), 
      lipoprotein-associated phospholipase A2 (LP-PLA2), secretory phospholipase A2 
      (sPLA2)] were detected. Pathological changes of thoracic aorta were observed by 
      HE staining. Protein and gene expressions of LP-PLA2 and sPLA2 in thoracic aorta 
      were measured by Western blot and real-time fluorescent quantitative PCR 
      respectively. RESULTS: Compared with the normal control group, rats in the model 
      group were in low spirits and responded poorly. Typical atherosclerotic plaque 
      could be seen in thoracic aorta of rats in the model group. Serum levels of TC, 
      TG, LDL-C, IL-6, TNF-alpha, MCP-1, ox-LDL, LP-PLA2, and sPLA2 significantly increased 
      (P < 0.05); protein and gene expressions of LP-PLA2 and sPLA2 in rat thoracic 
      aorta increased (P < 0.05) in the model group. After 8 weeks of intervention, 
      rats in 3 medication groups appeared active, and HE staining showed subsidence of 
      plaque in rat thoracic aorta. Compared with the model group, serum levels of TC, 
      TG, LDL-C, IL-6, TNF-alpha, MCP-1, ox-LDL, and LP-PLA2 decreased in 3 medication 
      groups (P < 0.01, P < 0.05); serum sPLA2 level decreased, protein and mRNA 
      expressions of LP-PLA2 and sPLA2 in rat thoracic aorta decreased in the WM group 
      (P < 0.01, P < 0.05); protein and mRNA expressions of LP-PLA2 in rat thoracic 
      aorta significantly decreased in the low dose DT group (P < 0.01, P < 0.05), and 
      those of LP-PLA2 and sPLA2 decreased in the high dose DT group (P < 0.01, P < 
      0.05). CONCLUSION: DT could fight against inflammatory reaction and AS possibly 
      through inhibiting LP-PLA2 expression and reducing ox-LDL production.
FAU - Chen, Jie
AU  - Chen J
FAU - Cai, Hong-wen
AU  - Cai HW
FAU - Miao, Jing
AU  - Miao J
FAU - Xu, Xiao-ming
AU  - Xu XM
FAU - Mao, Wei
AU  - Mao W
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhongguo Zhong Xi Yi Jie He Za Zhi
JT  - Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese 
      journal of integrated traditional and Western medicine
JID - 9211576
RN  - 0 (Chemokine CCL2)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Interleukin-6)
RN  - 0 (Lipids)
RN  - 0 (Lipoproteins, LDL)
RN  - 0 (Tablets)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (oxidized low density lipoprotein)
RN  - EC 3.1.1.4 (Phospholipases A2)
RN  - EC 3.1.1.47 (1-Alkyl-2-acetylglycerophosphocholine Esterase)
SB  - IM
MH  - 1-Alkyl-2-acetylglycerophosphocholine Esterase/blood
MH  - Animals
MH  - Aorta, Thoracic/pathology
MH  - Atherosclerosis/*drug therapy
MH  - Chemokine CCL2/blood
MH  - Drugs, Chinese Herbal/*pharmacology
MH  - Inflammation/*drug therapy
MH  - Interleukin-6/blood
MH  - Lipids/blood
MH  - Lipoproteins, LDL/blood
MH  - Male
MH  - Phospholipases A2/blood
MH  - Plaque, Atherosclerotic
MH  - Random Allocation
MH  - Rats
MH  - Rats, Wistar
MH  - Tablets
MH  - Tumor Necrosis Factor-alpha/blood
EDAT- 2016/08/06 06:00
MHDA- 2016/10/01 06:00
CRDT- 2016/08/06 06:00
PHST- 2016/08/06 06:00 [entrez]
PHST- 2016/08/06 06:00 [pubmed]
PHST- 2016/10/01 06:00 [medline]
PST - ppublish
SO  - Zhongguo Zhong Xi Yi Jie He Za Zhi. 2016 Jun;36(6):703-8.